Ionis Pharmaceuticals Inc. Common Stock vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 2.1× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.07% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| IONS | ZGN | |
|---|---|---|
Market Cap | $7.10B | $3.44B |
Volume | 2,027,457 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $86.50 | $15.25 |
52-Week Low | $42.38 | $8.69 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.66B | $4.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →